Moreover, the majority of cases of BCMA loss occur by immune selection after anti-BCMA targeted immunotherapies, and the expression levels of BCMA in myeloma cells recover to the pretreatment levels at a later time. Here, TNFRSF17 is linked to plasma cell myeloma.